Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naive HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis

Next Previous
X
Search
Trial Profile

Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naive HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raltegravir (Primary) ; Efavirenz; Lamivudine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms REFLATE TB2

    • Most Recent Events

    • 02 Aug 2022 Results of secondary analysis assessing the incidence, severity and risk factors associated with Liver Enzyme Elevation among patients co-infected with HIV and tuberculosis receiving antiretroviral therapy, presented at the 24th International AIDS Conference.
    • 30 Oct 2021 Results (N=444) presented at the 18th European AIDS Conference
    • 01 Jun 2021 Results published in The Lancet Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top